Is Trabectedin already included in the scope of medical insurance reimbursement?

Trabectedin (Trabectedin) is an anti-tumor drug derived from marine organisms and has attracted much attention due to its unique mechanism of action. It mainly interferes with the division and growth of tumor cells by binding to the minor groove of DNA and affecting transcription factors and repair pathways. Currently, the drug has been approved for use in patients with soft tissue sarcoma and some ovarian cancer in Europe and the United States, and is often used as one of the second-line or third-line treatment options in clinical practice. However, as far as the Chinese market is concerned, trabectedin has not yet been officially launched, so it is naturally not included in the national medical insurance reimbursement catalog.

In the domestic oncology drug system, the core standards for medical insurance inclusion often include the safety, effectiveness, clinical necessity and economic accessibility of drugs. Although trabectedin has many years of application experience overseas, it is still not on the market due to the lack of large-scale clinical trial data in China and the fact that the import process and price system have not been fully established. For domestic patients, this means that relevant expenses cannot be reimbursed through medical insurance channels and they need to bear the drug expenses themselves.

It is worth noting that some patients with drug needs will choose to purchase trabectedin through formal and legal overseas channels. Common ones currently on the market include European original drugs and versions supplied in Hong Kong. Since these channels need to comply with international drug circulation regulations and quality standards, the authenticity and safety of drugs are relatively guaranteed. However, when patients choose to purchase drugs overseas, they still need to do so under the guidance of doctors to avoid risks caused by information asymmetry or irregular channels.

From the perspective of policy trends, China has been accelerating the introduction and review of innovative drugs in recent years. Many new cancer drugs that were only marketed in Europe and the United States in the past have entered the country through mechanisms such as "overseas multi-center data adoption" and "priority review". If trabectedin can complete domestic registration and approval in the future and be integrated with the medical insurance negotiation mechanism, it is expected to gradually reduce the price and benefit more patients. .

Reference materials:https://www.drugs.com/monograph/trabectedin.html